Adherence of Renal Transplant Recipients to Once-daily, Prolonged-Release and Twice-daily, Immediate-release Tacrolimus-based Regimens in a Real-life Setting in Sweden

被引:11
|
作者
Fellstrom, B. [1 ]
Holmdahl, J. [2 ]
Sundvall, N. [3 ]
Cockburn, E. [4 ]
Kilany, S. [4 ]
Wennberg, L. [5 ,6 ,7 ]
机构
[1] Uppsala Univ, Dept Med Sci, Uppsala, Sweden
[2] Univ Gothenburg, Sahlgrenska Acad, Dept Nephrol, Gothenburg, Sweden
[3] Sunderby Hosp, Unit Nephrol, Lulea, Sweden
[4] Astellas Pharma, Kastrup, Denmark
[5] Karolinska Univ Hosp, Div Transplantat Surg, Huddinge, Sweden
[6] Karolinska Univ Hosp, CLINTEC, Huddinge, Sweden
[7] Karolinska Inst, Stockholm, Sweden
关键词
MEDICATION ADHERENCE; GRAFT FAILURE; KIDNEY; CONVERSION; PROGRAF; TRIAL; IMMUNOSUPPRESSANTS; NONCOMPLIANCE; FORMULATION; ADVAGRAF;
D O I
10.1016/j.transproceed.2018.06.027
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. In this study we investigated medication adherence of kidney transplant patients (KTPs) to an immediate-release tacrolimus (IR-T) regimen and, after conversion, to a prolonged-release tacrolimus (PR-T) regimen in routine clinical practice. Methods. This was a non-interventional, observational, multicenter Swedish study. We included adult KTPs with stable graft function, remaining on IR-T or converting from IR-T to PR-T. Data were collected at baseline, and months 3, 6, and 12 post-baseline. The primary endpoint was adherence using the Basel Assessment of Adherence to Immunosuppressive Medication Scale (BAASIS). Secondary assessments included tacrolimus dose and trough levels, clinical laboratory parameters (eg, estimated glomerular filtration rate), and adverse drug reactions (ADRs). Results. Overall, data from 233 KTPs were analyzed (PR-T, n = 175; IR-T, n = 58). Mean change in PR-T dose from baseline (4.8 mg/d) to month 12 was -0.2 mg/d, and for IR-T (4.2 mg/d) was-0.4 mg/d; tacrolimus trough levels remained similar. Overall adherence was similar between baseline and month 12 in both groups (PR-T: 54.4% vs 57.0%, respectively; IR-T: 65.5% vs 69.4%); timing adherence followed a similar pattern. The probability of taking adherence improved between baseline and month 12 (odds ratio, 1.97; P =.0092) in the PR-T group only. Mean BAASIS visual analog scale score at baseline was 94.3 11.1% (PR-T) and 95.3 7.6% (IR-T), and >95% at subsequent visits. Laboratory parameters remained stable. Eight (4.6%) patients receiving PR-T (none receiving IR-T) had ADRs considered probably/possibly treatment-related. Conclusion. Disparity existed between high, patient-perceived and low, actual adherence. Overall adherence to the immunosuppressive regimen (measured by BAASIS) did not improve significantly over 12 months in stable KTPs converting to PR-T or remaining on IR-T; renal function remained stable.
引用
收藏
页码:3275 / 3282
页数:8
相关论文
共 50 条
  • [1] Adherence of Renal Transplant Recipients to Once-daily, Prolonged-Release and Twice-daily, Immediate-release Tacrolimus-based Regimens in a Real-life Setting in Sweden (vol 50, pg 3275, 2018)
    Fellstrom, B.
    Holmdahl, J.
    Sundvall, N.
    Cockburn, E.
    Kilany, S.
    Wennberg, L.
    [J]. TRANSPLANTATION PROCEEDINGS, 2020, 52 (10) : 3238 - 3245
  • [2] A Multicenter, Prospective, Observational Study of Conversion from Twice-Daily Immediate-Release to Once-Daily Prolonged-Release Tacrolimus in Liver Transplant Recipients in France: The COBALT Study
    Dumortier, Jerome
    Duvoux, Christophe
    Dubel, Laurence
    Bazin, Fabienne
    Houssel-Debry, Pauline
    [J]. ANNALS OF TRANSPLANTATION, 2019, 24 : 506 - 516
  • [3] Once-daily prolonged-release tacrolimus versus twice-daily tacrolimus in liver transplantation
    Huang, Bingsong
    Liu, Jun
    Li, Jun
    Schroder, Paul M.
    Chen, Maogen
    Deng, Ronghai
    Deng, Suxiong
    [J]. JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2019, 59 (06) : 816 - +
  • [4] Safety of Conversion From Twice-Daily Tacrolimus (Prograf) to Once-Daily Prolonged-Release Tacrolimus (Advagraf) in Stable Liver Transplant Recipients
    Comuzzi, C.
    Lorenzin, D.
    Rossetto, A.
    Faraci, M. G.
    Nicolini, D.
    Garelli, P.
    Bresadola, V.
    Toniutto, P.
    Soardo, G.
    Baroni, G. S.
    Adani, G. L.
    Risaliti, A.
    Baccarani, U.
    [J]. TRANSPLANTATION PROCEEDINGS, 2010, 42 (04) : 1320 - 1321
  • [5] Tacrolimus Exposure Before and After a Switch From Twice-Daily Immediate-Release to Once-Daily Prolonged Release Tacrolimus: The ENVARSWITCH Study
    Monchaud, Caroline
    Woillard, Jean-Baptiste
    Crepin, Sabrina
    Tafzi, Naima
    Micallef, Ludovic
    Rerolle, Jean-Philippe
    Dharancy, Sebastien
    Conti, Filomena
    Choukroun, Gabriel
    Thierry, Antoine
    Buchler, Matthias
    Salame, Ephrem
    Garrouste, Cyril
    Duvoux, Christophe
    Colosio, Charlotte
    Merville, Pierre
    Anglicheau, Dany
    Etienne, Isabelle
    Saliba, Faouzi
    Mariat, Christophe
    Debette-Gratien, Marilyne
    Marquet, Pierre
    [J]. TRANSPLANT INTERNATIONAL, 2023, 36
  • [6] Once-Daily Prolonged-Release Tacrolimus (ADVAGRAF) Versus Twice-Daily Tacrolimus (PROGRAF) in Liver Transplantation
    Trunecka, P.
    Boillot, O.
    Seehofer, D.
    Pinna, A. D.
    Fischer, L.
    Ericzon, B-G
    Trois, R. I.
    Baccarani, U.
    Ortiz de Urbina, J.
    Wall, W.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (10) : 2313 - 2323
  • [7] CONVERSION FROM TWICE-DAILY TACROLIMUS (Prograf®) TO ONCE-DAILY PROLONGED RELEASE TACROLIMUS (Advagraf®) IN LIVER TRANSPLANT RECIPIENTS
    Del Gaudio, Massimo
    Cescon, Matteo
    Ercolani, Giorgio
    Cucchetti, Alessandro
    Zanello, Matteo
    Dazzi, Alessandro
    Lauro, Augusto
    Ravaioli, Matteo
    Morelli, Cristina
    Pinna, Antonio Daniele
    [J]. TRANSPLANT INTERNATIONAL, 2011, 24 : 249 - 249
  • [8] Safety and Efficacy Conversion from Twice-Daily Tacrolimus (Prograf) to Once-Daily Prolonged-Release Tacrolimus (Adavagraf) in Stable Liver Transplant Recipients
    Li, Chiu-Yen
    Wu, Chih-I
    Chen, Yao-Li
    Ng, Sock-Ping
    Chien, Su-Yu
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 74 - 74
  • [9] Safety and Efficacy of Conversion from Twice-Daily Tacrolimus (Prograf) to Once-Daily Prolonged-Release Tacrolimus (Graceptor) in Stable Kidney Transplant Recipients
    Nakamura, Y.
    Hama, K.
    Katayama, H.
    Soga, A.
    Toraishi, T.
    Yokoyama, T.
    Kihara, Y.
    Jojima, Y.
    Konno, O.
    Iwamoto, H.
    Takeuchi, H.
    Hirano, T.
    Shimazu, M.
    [J]. TRANSPLANTATION PROCEEDINGS, 2012, 44 (01) : 124 - 127
  • [10] Conversion From Once-Daily Prolonged-Release Tacrolimus to Once-Daily Extended-Release Tacrolimus in Stable Liver Transplant Recipients
    Altieri, Mario
    Delaval, Guillaume
    Kimmoun, Elisabeth
    Allaire, Manon
    Salame, Ephrem
    Dumortier, Jerome
    [J]. EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2018, 16 (03) : 321 - 325